Home » Stocks » DYAI

Dyadic International, Inc. (DYAI)

Stock Price: $5.56 USD 0.25 (4.71%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 152.53M
Revenue (ttm) 1.69M
Net Income (ttm) -9.10M
Shares Out 27.48M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE 14.47
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $5.56
Previous Close $5.31
Change ($) 0.25
Change (%) 4.71%
Day's Open 5.39
Day's Range 5.32 - 5.60
Day's Volume 87,152
52-Week Range 2.58 - 10.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 1 week ago

JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 g...

Seeking Alpha - 5 months ago

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2020 Results - Earnings Call Transcript

The Motley Fool - 6 months ago

This small-cap stock is developing a technology that could revolutionize biotech.

Seeking Alpha - 8 months ago

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

Dyadic International: The Pandemic Changes Everything

Seeking Alpha - 9 months ago

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q4 2019 Results - Earnings Call Transcript

Benzinga - 10 months ago

Dyadic International, Inc. (NASDAQ: DYAI) shares are trading higher on Thursday, after the company announced its platform is to be used by the Israeli Research Institution to develop a treatme...

24/7 Wall Street - 11 months ago

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

Other stocks mentioned: AHPI, APT, BCRX, CERS, CODX, INO, LAKE, MRNA, NNVC, NVAX, VIR
Seeking Alpha - 1 year ago

Dyadic International: Disrupting Biopharma Delivery And Costs

Seeking Alpha - 1 year ago

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Company’s lead product promises to greatly speed development and reduce costs of producing biologic drugs, which is currently being tested by major collaborators and at least two big pharma pl...

About DYAI

Dyadic International, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research... [Read more...]

Industry
Biotechnology
IPO Date
Nov 5, 2004
CEO
Mark A. Emalfarb
Employees
6
Stock Exchange
NASDAQ
Ticker Symbol
DYAI
Full Company Profile

Financial Performance

In 2019, DYAI's revenue was $1.68 million, an increase of 29.77% compared to the previous year's $1.30 million. Losses were -$8.31 million, 46.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is 11.00.

Price Target
$11.00
Analyst Consensus: Strong Buy